ClinicalTrials.gg
CompletedNCT06800560Updated Jan 30, 2025

The Development, Validation and Application of a Novel Questionnaire Developed by ZOE Ltd Measuring Menopause Symptoms and Subjective Quality of Life

An observational study in Menopause, sponsored by Zoe Global Limited. Completed at 1 site in United Kingdom. Open to female participants aged 37 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-01-30.

Sponsored by Zoe Global Limited · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
1,100
Ages
37 Years to 70 Years
Sex
Female
01

Study summary

The MenoScale has been developed from the most common symptoms identified in over 70,000 women to reflect symptom prevalence and user-friendly terminology. It builds and improves on pre-existing scoring tools in four main ways. Firstly, the symptoms assessed are informed by prevalence, as identified from a large cohort. Secondly, the language used to ask about symptoms is modern and accessible as determined through qualitative user research. Thirdly, the impact on quality of life is assessed. Finally, it is already being offered online and completely open access.

The overall aim of this study is to validate the reliability and validity of the MenoScale as an instrument to measure menopausal symptoms and the related subjective impact on quality of life (QoL).

Read the detailed description

Menopause, a crucial phase in a woman's life, is the disappearance of menstruation for 12 months or longer due to depleted ovarian activity. On average, this stage accounts for over one-third of a woman's lifespan (1). In the United Kingdom (UK), the average age of menopause is 51 years, with the transitional period known as perimenopause occurring from around 45 years (2). As of 2017, there are 13 million menopausal women in the UK, with one third being aged 50 years and over in full time employment (3). It is crucial to have reliable and accessible methods for measuring and tracking symptoms in order to establish medical and lifestyle interventions which may aid in alleviating the burden of these symptoms.

All stages of menopause is accompanied by a wide variety of fluctuating symptoms and subjective experiences of women. Therefore, an online, validated questionnaire offers women the opportunity to monitor their symptoms in real- time which ultimately will: 1) raise awareness by increasing understanding around menopause; 2) empower women to track and manage their menopause themselves; and 3) facilitate conversations by providing data-backed insights to enhance discussions with healthcare providers.

The study has four main objectives:

  1. Validate the ability of the MenoScale to measure the prevalence of menopause-related symptoms in comparison to the most widely-used scale in clinical practice.
  2. Validate the ability of the MenoScale to measure the impact that symptoms have on overall QoL in comparison to a widely-used QoL scale.
  3. Evaluate the test-retest reliability of the MenoScale.
  4. Explore relationships between menopause-related symptoms and dietary intake.

RECRUITMENT: Potential participants will be recruited from those who are enrolled onto the ZOE Health Study as well as their friends and family. Potential participants will be contacted via email and provided with a Participant Information Sheet. Participants will be given a minimum of 24 hours after receiving the information sheet to decide whether they would like to take part in the study. Those that would like to take part in the study will be screened using an online form via a secure survey platform and eligible participants will then be asked to provide informed consent.

STUDY DESIGN: Once informed consent has been provided all participants will be asked to complete online versions of a demographics questionnaire (ethnicity, education level, menopause history [age symptoms started, age of last period], HRT usage [type and time period taken]), the MenoScale, Green Climacteric Scale, and the Short Form-36. Participants will also be asked to completed a food frequency questionnaire at baseline only. Participants will be contacted seven days later to repeat the same procedures - except for the demographics, health questionnaire and FFQ. Completion of all questionnaires is expected to take approximately 1 hour at baseline and 15 minutes at follow up.

Biological samples will not be collected in this study, nor will previously collected data be analysed.

The only primary data collection to occur during this study is the following:

  • Menopause symptoms questionnaires: MenoScale and Green Climacteric Scale
  • Quality of life questionnaire: Short Form 36
  • Dietary questionnaire: Predict-Food Frequency Questionnaire-v1
  • Demographics questionnaire: ethnicity, BMI, HRT usage, education

References:

  1. Bermingham KM, Linenberg I, Hall WL, Kadé K, Franks PW, Davies R, Wolf J, Hadjigeorgiou G, Asnicar F, Segata N, Manson JE, Newson LR, Delahanty LM, Ordovas JM, Chan AT, Spector TD, Valdes AM, Berry SE. Menopause is associated with postprandial metabolism, metabolic health and lifestyle: The ZOE PREDICT study. EBioMedicine. 2022 Nov;85:104303. doi: 10.1016/j.ebiom.2022.104303.
  2. Gatenby C, Simpson P. Menopause: Physiology, definitions, and symptoms. Best Pract Res Clin Endocrinol Metab. 2024 Jan;38(1):101855. doi: 10.1016/j.beem.2023.101855.
  3. Menopause transition: effects on women's economic participation - GOV.UK [https://www.gov.uk/government/publications/menopause-transition-effects-on-womens-economic-participation]
02

Conditions studied

  • Menopause

Keywords

  • Menopause
  • Questionnaire Validation
  • Perimenopause
  • Postmenopause
  • Quality of Life
  • Diet Quality
  • Menopausal Symptoms
03

In context

Lead sponsor

Zoe Global Limited is the lead sponsor of 9 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
37 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The participants for this study will be recruited from the ZOE Health Study, which is a community science app in which participants are actively involved in logging lifestyle and health data, and those who have consented to receiving the ZOE newsletter.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Female (sex assigned at birth) Aged 37 - 70 years Peri- or (self-reported)

Exclusion criteria

Exclusion Criteria:

Currently pregnant and/or lactating History of hysterectomy or oophorectomy History of treatment-induced menopause of \< 18.5 Subject is taking > 5 prescribed medications Subject is unable to provide online Subject is unable understand the participant information sheet Subject is unable to complete the questionnaires online

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
1,100 participants (actual)
Patient registry
No

Groups and cohorts

  • PeriHRT - perimenopausal women currently using hormone replacement therapy

    Sub-cohort

    Other: MenoScale · Other: Greene Climacteric Scale · Other: RAND 36-Item Health Survey 1.0 · Other: PREDICT-FFQ-v1

  • Peri - perimenopausal women not using hormone replacement therapy

    Sub-cohort

    Other: MenoScale · Other: Greene Climacteric Scale · Other: RAND 36-Item Health Survey 1.0 · Other: PREDICT-FFQ-v1

  • PostHRT - postmenopausal women currently using hormone replacement therapy

    Sub-cohort

    Other: MenoScale · Other: Greene Climacteric Scale · Other: RAND 36-Item Health Survey 1.0 · Other: PREDICT-FFQ-v1

  • Post - postmenopausal women not using hormone replacement therapy

    Sub-cohort

    Other: MenoScale · Other: Greene Climacteric Scale · Other: RAND 36-Item Health Survey 1.0 · Other: PREDICT-FFQ-v1

Interventions

  • OtherMenoScale

    Menopause symptom questionnaire

  • OtherGreene Climacteric Scale

    Menopause symptom questionnaire

  • OtherRAND 36-Item Health Survey 1.0

    Quality of life questionnaire

    Also known as: Short Form 36, SF36, SF-36

  • OtherPREDICT-FFQ-v1

    Food frequency questionnaire

    Also known as: Food frequency questionnaire, FFQ

06

What researchers measure

Primary outcomes

  1. MenoScale validity for menopause symptoms

    The ability of the MenoScale to measure the prevalence of menopause-related symptoms in comparison to the most widely-used scale in clinical practice.

    Time frame: Baseline

Secondary outcomes

  1. MenoScale validity for quality of life

    - The ability of the MenoScale to measure the impact that symptoms have on overall quality of life in comparison to a widely-used quality of life scale.

    Time frame: Baseline

  2. MenoScale reliability

    The reliability of the MenoScale to be repeated and how this compares to the Green Climacteric Scale

    Time frame: Baseline and 1 week later

  3. Diet quality

    Associations between healthy dietary patterns, food groups and menopausal symptoms

    Time frame: Baseline

07

Study locations

1 site
  • ZOE Ltd
    London, United Kingdom
08

References and documents

Publications

  • Gatenby C, Simpson P. Menopause: Physiology, definitions, and symptoms. Best Pract Res Clin Endocrinol Metab. 2024 Jan;38(1):101855. doi: 10.1016/j.beem.2023.101855. Epub 2023 Dec 21. PubMed 38171939 ↗
  • Bermingham KM, Linenberg I, Hall WL, Kade K, Franks PW, Davies R, Wolf J, Hadjigeorgiou G, Asnicar F, Segata N, Manson JE, Newson LR, Delahanty LM, Ordovas JM, Chan AT, Spector TD, Valdes AM, Berry SE. Menopause is associated with postprandial metabolism, metabolic health and lifestyle: The ZOE PREDICT study. EBioMedicine. 2022 Nov;85:104303. doi: 10.1016/j.ebiom.2022.104303. Epub 2022 Oct 18. PubMed 36270905 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2024 to primary completion in Dec 2024, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2024
First posted
Jan 30, 2025
StartActual
Nov 12, 2024
Primary completionActual
Dec 11, 2024
CompletionActual
Dec 17, 2024
Last update
Jan 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06800560
Lead sponsor
Zoe Global Limited
Responsible party
Sponsor
First posted
Jan 30, 2025
Start date
Nov 12, 2024
Primary completion
Dec 11, 2024
Completion
Dec 17, 2024
Last update
Jan 30, 2025

Study contacts

Sarah Berry, PhD
principal investigator · King's College London

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion